Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–47. https://doi.org/10.1016/j.jhep.2019.06.021.

Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20–30. https://doi.org/10.1016/S2468-1253(22)00317-X.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. https://doi.org/10.1002/cld.722.

Article  PubMed  Google Scholar 

Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;22:23–37. https://doi.org/10.1016/j.cld.2017.08.007.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999–2014. https://doi.org/10.1053/j.gastro.2019.11.312.

Article  CAS  PubMed  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. https://doi.org/10.1038/s41591-018-0104-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:101238. https://doi.org/10.1016/j.molmet.2021.101238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simantiris S, Antonopoulos AS, Papastamos C, et al. Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease. J Clin Lipidol. 2023;17:55–63. https://doi.org/10.1016/j.jacl.2022.10.004.

Article  PubMed  Google Scholar 

Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61:1294–303. https://doi.org/10.1007/s10620-016-4049-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67:154–66. https://doi.org/10.1093/clinchem/hvaa247.

Article  PubMed  Google Scholar 

Bhatia HS, Wilkinson MJ. Lipoprotein(a): Evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11:6040. https://doi.org/10.3390/jcm11206040.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koruk M, Savaş MC, Yilmaz O, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003;37:177–82. https://doi.org/10.1097/00004836-200308000-00017.

Article  CAS  PubMed  Google Scholar 

Priya MT, Sheriff DS. A preliminary study of inflammatory markers in non-alcoholic steatohepatitis patients. Libyan J Med. 2010;5. https://doi.org/10.3402/ljm.v5i0.5071.

Choe YG, Jin W, Cho YK, et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J Gastroenterol Hepatol. 2013;28:678–83. https://doi.org/10.1111/jgh.12077.

Article  CAS  PubMed  Google Scholar 

Nam JS, Jo S, Kang S, Ahn CW, Kim KR, Park JS. Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. Clin Chim Acta. 2016;461:14–8. https://doi.org/10.1016/j.cca.2016.07.003.

Article  CAS  PubMed  Google Scholar 

Zhang Y, He H, Zeng YP, et al. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study. Lipids Health Dis. 2020;19:134. https://doi.org/10.1186/s12944-020-01310-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jung I, Kwon H, Park SE, et al. Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease. Atherosclerosis. 2020;308:1–5. https://doi.org/10.1016/j.atherosclerosis.2020.07.020.

Article  CAS  PubMed  Google Scholar 

Wu T, Ye J, Shao C, et al. Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease. Front Endocrinol (Lausanne). 2021;12:691556. https://doi.org/10.3389/fendo.2021.691556.

Article  PubMed  PubMed Central  Google Scholar 

Esteve-Luque V, Padró-Miquel A, Fanlo-Maresma M, et al. Implication between genetic variants from APOA5 and ZPR1 and NAFLD severity in patients with hypertriglyceridemia. Nutrients. 2021;13:552. https://doi.org/10.3390/nu13020552.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sukahri S, Mohamed Shah FZ, Ismail AI, et al. Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease. PLoS One. 2021;16:e0253298. https://doi.org/10.1371/journal.pone.0253298.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu T, Ye J, Shao C, et al. The ability of lipoprotein (a) level to predict early carotid atherosclerosis Is impaired in patients with advanced liver fibrosis relared to metabolic-associated fatty liver disease. Clin Transl Gastroenterol. 2022;13:e00504. https://doi.org/10.14309/ctg.0000000000000504.

Article  PubMed  PubMed Central  Google Scholar 

Arya S, Kaji AH, Boermeester MA. PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg. 2021;156:789–90. https://doi.org/10.1001/jamasurg.2021.0546.

Article  PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.

Article  PubMed  PubMed Central  Google Scholar 

Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 2001;92:301–5.

CAS  PubMed  Google Scholar 

Malaguarnera M, Giugno I, Trovato BA, Panebianco MP, Siciliano R, Ruello P. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther. 1995;17:721–8. https://doi.org/10.1016/0149-2918(95)80048-4.

Article  CAS  PubMed  Google Scholar 

Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80:934–46. https://doi.org/10.1016/j.jacc.2022.06.019.

Article  CAS  PubMed  Google Scholar 

Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009;119:1711–9. https://doi.org/10.1161/CIRCULATIONAHA.108.836940.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silva WA, Almeida-Pititto B, Santos RB, et al. Obstructive sleep apnea is associated with lower adiponectin and higher cholesterol levels independently of traditional factors and other sleep disorders in middle-aged adults: the ELSA-Brasil cohort. Sleep Breath. 2021;25:1935–44. https://doi.org/10.1007/s11325-021-02290-7.

Article  PubMed  Google Scholar 

Xu H, Xia Y, Li X, et al. Association between obstructive sleep apnea and lipid metabolism during REM and NREM sleep. J Clin Sleep Med. 2020;16:475–82. https://doi.org/10.5664/jcsm.8242.

Article  PubMed  PubMed Central  Google Scholar 

Konishi K, Miyake T, Furukawa S, et al. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis. 2020;299:32–7. https://doi.org/10.1016/j.atherosclerosis.2020.02.026.

Article  CAS  PubMed  Google Scholar 

Meroni M, Longo M, Lombardi R, et al. Low lipoprotein(a) levels predict hepatic fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Commun. 2022;6:535–49. https://doi.org/10.1002/hep4.1830.

Article  CAS  PubMed  Google Scholar 

Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. https://doi.org/10.1016/j.atherosclerosis.2022.04.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94. https://doi.org/10.1016/j.jacc.2019.10.019.

Article  CAS  PubMed  Google Scholar 

Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1:220–7. https://doi.org/10.1016/S2213-8587(13)70064-0.

Article  CAS  PubMed  Google Scholar